Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Early Childhood Obesity Programming by Intrauterine Growth RestrictionCompleted
NCT03402139N/AUpdated Aug 31, 2026
Sponsor: Montefiore Medical Center
Childhood Obesity · Epigenetics
United States
HPV Vaccine Reduced DoseRecruiting
NCT06799494Phase 4Updated Aug 31, 2026
Sponsor: Emory University
HPV
United States
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)Not Yet Recruiting
NCT07700758Phase 2Updated Aug 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)Not Yet Recruiting
NCT07793942Phase 2Updated Aug 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplam · Advanced Solid Tumors
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active Not Recruiting
NCT05171816Phase 3Updated Aug 28, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
China
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Recruiting
NCT06941272Phase 1, Phase 2Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Australia, Belgium, Brazil, Colombia +16 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Recruiting
NCT06637423Phase 1, Phase 2Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-Muscle Invasive Bladder Cancer
United States, Canada, France, Netherlands, Spain +1 more
First In Human Study of CX-801 in Advanced Solid TumorsRecruiting
NCT06462794Phase 1Updated Aug 28, 2026
Sponsor: CytomX Therapeutics
Solid Tumor, Adult
United States
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)Recruiting
NCT07030712Phase 1Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Neoplasm
United States, Israel, Netherlands
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Recruiting
NCT06979596Phase 2Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Argentina, Brazil, Canada, Chile +8 more
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)Recruiting
NCT06655883Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Insomnia
United States
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)Not Yet Recruiting
NCT07748351Phase 1Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)Active Not Recruiting
NCT06132958Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)Completed
NCT05298423Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Brazil, Chile +20 more
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDCompleted
NCT07016412Phase 2Updated Aug 28, 2026
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
United States
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Recruiting
NCT05714085Phase 2, Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Heart Failure · Left Ventricular Systolic Dysfunction
United States, Belgium, Brazil, Canada, Colombia +25 more
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Recruiting
NCT07363590Phase 1Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Australia, Belgium, China, Colombia, Georgia +5 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Recruiting
NCT06952504Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Cancer
United States, Argentina, Australia, Austria, Belgium +29 more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Recruiting
NCT07060807Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Brazil, Canada +21 more
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Recruiting
NCT07431827Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Argentina, Australia, Brazil, Canada, Chile +12 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Active Not Recruiting
NCT06459180Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Australia, Austria, Belgium +27 more
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active Not Recruiting
NCT06428396Phase 2Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Breast Cancer
United States, Argentina, Canada, Chile, Colombia +4 more
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Recruiting
NCT07071623Phase 3Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
Kenya, South Africa, Uganda
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Recruiting
NCT06596694Phase 1, Phase 2Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastrointestinal Cancer
United States, Australia, Canada, Chile, China +10 more
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)Completed
NCT06460961Phase 1Updated Aug 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Neoplasm Metastasis
United States, Australia, Canada, Israel

Previous page Next page